Promimic (PRO) Q1 2026 earnings summary

Executive summary

• Achieved positive cash flow of 1.0 MSEK for Q1 2026, with net sales of 8.8 MSEK, reflecting 1% growth in SEK and 18% currency-adjusted growth year-over-year.

• Core business revenues from implants grew 23% currency-adjusted and 5% in SEK.

• Customer milestones included FDA recognition for Curiteva and 10,000 operations for Able Medical.

• Investments in US subsidiary Nano Processing Inc. are expected to drive future profitability and growth.

Financial highlights

• Net sales: 8.8 MSEK (8.8 MSEK Q1 2025); total operating income: 9.5 MSEK (11.0 MSEK Q1 2025).

• Operating result: -3.5 MSEK (-3.7 MSEK Q1 2025); net result after tax: -3.5 MSEK (-4.5 MSEK Q1 2025).

• Earnings per share: -0.18 SEK (-0.24 SEK Q1 2025).

• Cash flow for the period: 1.0 MSEK (-0.9 MSEK Q1 2025); cash at period end: 21.9 MSEK (34.1 MSEK Q1 2025).

• Equity ratio: 78% (82% Q1 2025).

Outlook and guidance

• Management remains optimistic due to increased customer inquiries and project starts in early 2026.

• Focus on capitalizing on US investments and maintaining cost control to improve profitability.

• Strategic priority on US market expansion and new applications.

• Long-term targets: >25% CAGR annual growth and >40% EBITDA margin.